Monday, 2 November 2026
M
Meridian Globe
Live briefing
Nuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaThai reformists became too technocratic, party ex-leader Pita says— 日经 Nikkei AsiaJapan bamboo chopsticks catch on in South Korea— 日经 Nikkei AsiaOn India's east coast, tidepooling inspires marine conservation— 日经 Nikkei AsiaNuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaThai reformists became too technocratic, party ex-leader Pita says— 日经 Nikkei AsiaJapan bamboo chopsticks catch on in South Korea— 日经 Nikkei AsiaOn India's east coast, tidepooling inspires marine conservation— 日经 Nikkei Asia

Pembrolizumab plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer with PD-L1 CPS ≥ 1: a cost-effectiveness analysis

Source Nature 医学研究2d ago
Summary

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
Health
Region
Global
Language
English
Item ID
health-c6740a8b

Comments 0 comments

No comments yet. Be the first.

Pembrolizumab plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer with PD-L1 CPS ≥ 1: a cost-effectiveness analysis · Meridian Globe